ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,210.00
0.39%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Protagonist Therapeutics Inc (PTGX)

  7. Protagonist Therapeutics Inc (PTGX) Noticias

PTGX

Protagonist Therapeutics (PTGX)

Protagonist Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PTGX
FechaHoraFuenteTítuloSímboloCompañía
07/05/202415:51Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTGXProtagonist Therapeutics Inc
07/05/202415:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTGXProtagonist Therapeutics Inc
16/04/202408:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:PTGXProtagonist Therapeutics Inc
01/03/202419:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
01/03/202419:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202406:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTGXProtagonist Therapeutics Inc
18/12/202315:15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTGXProtagonist Therapeutics Inc
11/08/202315:32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PTGXProtagonist Therapeutics Inc
12/05/202306:00PR Newswire (US)Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113NASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202315:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Life Sciences ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
11/05/202309:17PR Newswire (US)Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology AssociationNASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202315:39Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202315:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTGXProtagonist Therapeutics Inc
04/05/202315:05PR Newswire (US)Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
19/04/202315:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTGXProtagonist Therapeutics Inc
12/04/202316:17Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PTGXProtagonist Therapeutics Inc
06/04/202305:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202316:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTGXProtagonist Therapeutics Inc
15/03/202315:52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTGXProtagonist Therapeutics Inc
08/03/202301:05Dow Jones NewsProtagonist Therapeutics Sees Positive Topline Results in JNJ-2113 TrialNASDAQ:PTGXProtagonist Therapeutics Inc
07/03/202307:00PR Newswire (US)Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in PsoriasisNASDAQ:PTGXProtagonist Therapeutics Inc
14/02/202315:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTGXProtagonist Therapeutics Inc
09/02/202310:45Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTGXProtagonist Therapeutics Inc
21/12/202215:05PR Newswire (US)Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTGXProtagonist Therapeutics Inc
01/12/202206:05PR Newswire (US)Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology SummitNASDAQ:PTGXProtagonist Therapeutics Inc
17/11/202217:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTGXProtagonist Therapeutics Inc
16/11/202215:05PR Newswire (US)Protagonist Therapeutics Reports Granting of Inducement AwardNASDAQ:PTGXProtagonist Therapeutics Inc
13/11/202222:10TipRanksAnalysts Are Bullish on Top Healthcare Stocks: Passage Bio (PASG), Privia Health Group (PRVA)NASDAQ:PTGXProtagonist Therapeutics Inc
09/11/202215:15TipRanksJMP Securities Remains a Buy on Protagonist Therapeutics (PTGX)NASDAQ:PTGXProtagonist Therapeutics Inc
08/11/202215:05PR Newswire (US)Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:PTGXProtagonist Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PTGX

Su Consulta Reciente

NYSE
OXY
Occidental Petroleum
COIN
OXDUST
0xDAO
NASDAQ
AAXJAXX
Royal Bank of Canada Cap...
BIT
SFVS1S
Societe Generale Effekten
TSXV
WMD.WT.A
WeedMD
ASX
BM8
Battery Age Minerals
NASDAQ
ABAZWXX
Citigroup Global Markets...
LATK
OMNIAUSDT
OmniaVerse
USOTC
FGABF
Fastighets Aktiebolaget (PK)
EU
BRAMO
Regiao Autonoma da Madeira
USOTC
FAUMF
First Amern Uranium (PK)
NASDAQ
GRPACX
Retirepilot Aggressive 2...
HITB
SUSHIUSD
SushiToken
EU
IBNKE
Lyxor BNKE iNav
TSXV
LABS
MediPharm Labs
USOTC
HHDS
Highlands REIT (CE)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados